@article {Levin-Rector2021.12.09.21267203, author = {Alison Levin-Rector and Lauren Firestein and Emily McGibbon and Jessica Sell and Sungwoo Lim and Ellen H. Lee and Don Weiss and Anita Geevarughese and Jane R. Zucker and Sharon K. Greene}, title = {Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults, June{\textendash}August 2021}, elocation-id = {2021.12.09.21267203}, year = {2021}, doi = {10.1101/2021.12.09.21267203}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Belief in immunity from prior infection and concern that vaccines might not protect against new variants are contributors to vaccine hesitancy. We assessed effectiveness of full and partial COVID-19 vaccination against reinfection when Delta was the predominant variant in New York City.Methods We conducted a case-control study in which case-patients with reinfection during June 15{\textendash} August 31, 2021 and control subjects with no reinfection were matched (1:3) on age, sex, timing of initial positive test in 2020, and neighborhood poverty level. Conditional logistic regression was used to calculate matched odds ratios (mOR) and 95\% confidence intervals (CI).Results Of 349,598 adult residents who tested positive for SARS-CoV-2 infection in 2020, did not test positive again \>90 days after initial positive test through June 15, 2021, and did not die before June 15, 2021, 1,067 were reinfected during June 15{\textendash}August 31, 2021. Of 1,048 with complete matching criteria data, 499 (47.6\%) were known to be symptomatic for COVID-19-like-illness, and 75 (7.2\%) were hospitalized. Unvaccinated individuals, compared with fully vaccinated individuals, had elevated odds of reinfection (mOR, 2.23; 95\% CI, 1.90, 2.61), of symptomatic reinfection (mOR, 2.17; 95\% CI, 1.72, 2.74), and of reinfection with hospitalization (mOR, 2.59; 95\% CI, 1.43, 4.69). Partially versus fully vaccinated individuals had 1.58 (95\% CI: 1.22, 2.06) times the odds of reinfection. All three vaccines authorized or approved for use in the U.S. were similarly effective.Conclusion Among adults with previous SARS-CoV-2 infection, vaccination reduced odds of reinfections when the Delta variant predominated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work beyond their usual salaries. ALR was supported by ELC CARES (grant No. NU50CK000517-01-09), funded by the US Centers for Disease Control and Prevention (CDC). LF was supported by the ELC COVID Data Analysis Project (BCD) (grant No. 4021-04Z), funded by CDC. SKG was supported by the Public Health Emergency Preparedness Cooperative Agreement (grant No. NU90TP922035-03-03), funded by CDC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was deemed public health surveillance that is non-research by the Department of Health and Mental Hygiene Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLine-level data are not publicly available in accordance with patient confidentiality and privacy laws. Publicly available data are linked below. https://www1.nyc.gov/site/doh/covid/covid-19-data.page}, URL = {https://www.medrxiv.org/content/early/2021/12/11/2021.12.09.21267203}, eprint = {https://www.medrxiv.org/content/early/2021/12/11/2021.12.09.21267203.full.pdf}, journal = {medRxiv} }